CELU
vs
S&P 500
CELU
S&P 500
Over the past 12 months, CELU has underperformed S&P 500, delivering a return of -42% compared to the S&P 500's +14% growth.
Stocks Performance
CELU vs S&P 500
Performance Gap
CELU vs S&P 500
Performance By Year
CELU vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Celularity Inc
Glance View
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company is headquartered in New York City, New York and currently employs 225 full-time employees. The company went IPO on 2019-05-23. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), unmodified and genetically modified natural killer (NK) cells, mesenchymal-like adherent stromal cells (ASCs), and targeting therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CyCART-19 is a placental-derived CAR-T cell therapy and targeting the CD19 receptor; CYNK-001 is for the treatment of acute myeloid leukemia (AML); CYNK-101 is genetically modified version of a placental-derived NK-cell; APPL-001 developed for the treatment of Crohn’s disease, a degenerative disease, and PDA-002 developed for the treatment of Facioscapulohumeral muscular dystrophy (FSHD).
